Chair and Department of Neurology, Jaczewskiego 8, 20-954 Lublin, Poland.
Neurol Neurochir Pol. 2020;54(3):252-258. doi: 10.5603/PJNNS.a2020.0037. Epub 2020 May 28.
Multiple Sclerosis (MS) is a chronic, demyelinating disease of the central nervous system which affects mostly young people. Because it leads to disability and cognitive impairment, it is crucial to recognise MS at an early stage.
Magnetic resonance imaging is the golden standard in MS diagnosis. However, it is not an infallible diagnostic tool, especially at the stage of clinically isolated syndrome. The incorporation of oligoclonal bands in the diagnostic process of MS is a step towards the extension of diagnostic methods. Recently, a lot of research has been carried out on potential biomarkers in blood serum and cerebrospinal fluid that may be useful in the diagnosis of MS.
This article summarises current knowledge on the use of new prognostic factors such as neurofilament light chain, chitinase 3-like 1 and 2, heat shock proteins, and tubulins in MS.
Despite numerous studies on the use of biomarkers in the diagnosis of MS, more extensive research is needed to determine the clinical usefulness of these molecules and to develop diagnostic tests applicable in everyday practice. This in turn may result in earlier MS detection, faster implementation of treatment, and better therapeutic effects.
多发性硬化症(MS)是一种影响年轻人的中枢神经系统慢性脱髓鞘疾病。由于它会导致残疾和认知障碍,因此早期识别 MS 至关重要。
磁共振成像(MRI)是 MS 诊断的金标准。然而,它并不是一种万无一失的诊断工具,尤其是在临床孤立综合征阶段。寡克隆带在 MS 诊断过程中的加入是扩展诊断方法的一步。最近,在血清和脑脊液中寻找可能有助于 MS 诊断的潜在生物标志物方面进行了大量研究。
本文总结了目前关于神经丝轻链、几丁质酶 3 样蛋白 1 和 2、热休克蛋白和微管蛋白等新的预后因素在 MS 中的应用的知识。
尽管有许多关于生物标志物在 MS 诊断中应用的研究,但仍需要进行更广泛的研究,以确定这些分子的临床实用性,并开发适用于日常实践的诊断测试。这反过来又可能导致更早地发现 MS,更快地实施治疗,并获得更好的治疗效果。